Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia

Published:2010-09-10 Issue:3 Volume:92 Page:481-489
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Kikuchi Misato,Tanaka Junji,Kondo Takeshi,Hashino Satoshi,Kasai Masaharu,Kurosawa Mitsutoshi,Iwasaki Hiroshi,Morioka Masanobu,Kawamura Tsugumichi,Masauzi Nobuo,Fukuhara Takashi,Kakinoki Yasutaka,Kobayashi Hajime,Noto Satoshi,Asaka Masahiro,Imamura Masahiro

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-010-0670-1.pdf

Reference22 articles.

1. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.

2. Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The polish adult leukemia group ALL 4-2002 MRD study. Br J Haematol. 2008;142:227–37.

3. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24:521–35.

4. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol. 2004;112:8–15.

5. Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, et al. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol. 2005;80:181–7.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study;Blood Neoplasia;2024-09

2. Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing;Hemato;2023-01-09

3. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia;Clinical Lymphoma Myeloma and Leukemia;2021-04

4. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph‐negative acute lymphoblastic leukemia;European Journal of Haematology;2019-07-05

5. Modeling Chemotherapy Resistant Leukemia In Vitro;Journal of Visualized Experiments;2016-02-09